Project Grant R01CA295762
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$472K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) will provide $606,869 to Case Western Reserve University from July 2024 through June 2029 to study the mechanisms of androgen receptor inverse agonists in treating advanced prostate cancer. The research aims to map the epigenetic mechanisms driving treatment-resistant metastatic castration-resistant prostate cancer, and to develop novel small molecule therapies that can functionally...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $571,271 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Texas Health Science Center at Houston (UTHealth) to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The key goals of the 5-year project are to: (1) synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate to selectively deliver the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $415,902 to the University of Massachusetts Boston to conduct research aimed at overcoming lineage plasticity and therapy resistance in castration-resistant prostate cancer. The key objectives are to: Determine if expression of the FOXA2 transcription factor can drive luminal prostate cancer cells into a multilineage transition state. This will involve assessing FOXA2 chromatin binding...
This Project Grant award of $683,979 from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), supports research by Weill Medical College of Cornell University to investigate the molecular mechanisms underlying prostate cancer progression and therapeutic resistance. The research aims to define how specific genetic alterations, particularly mutations in the SPOP gene, impact prostate cancer cell lineage fidelity and shape the development of...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $509,246 to the Regents of the University of Michigan to conduct research on early drivers of prostate cancer lineage plasticity. The key objectives are to: Determine the mechanisms by which transcriptional regulators modulate prostate cancer cell differentiation and hallmarks. Understand how these transcriptional regulators are upregulated in human prostate tumors and their association...
This Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports research to elucidate the noncanonical tumor-suppressive and transcription-repressive roles of the epigenetic regulator SETD7 in prostate cancer progression and therapy resistance. The $832,818 award, effective from December 2024 to November 2029, aims to: 1) assess SETD7 protein expression and its correlation with key epigenetic regulators in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $564,543 to Weill Medical College of Cornell University to conduct research on the role of the androgen receptor (AR) in prostate cancer. The research aims to: Determine the context that allows engagement of growth suppressive AR transcriptional programs in prostate cancer. Establish the translational implications of oncogenic and growth suppressive AR programs in...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports the development of VNPP433-3B, a novel therapeutic compound for the treatment of prostate cancer. The total funding amount is $1,022,522, with the award period running from June 4, 2025 to May 31, 2027. The key objectives of this award are to: 1) Synthesize 500g of non-GMP VNPP433-3B for preclinical studies, including characterization, formulation, and support...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $371,719 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The grant, titled "Towards Characterization of Epigenetic Targets in Prostate Cancer," aims to gain deeper mechanistic insights into how the histone methyltransferase NSD2 influences the...
The National Cancer Institute (NCI) awarded Emory University a $1,082,472 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to determine the molecular mechanisms underlying the progression of prostate adenocarcinoma (ADPC) to the lethal neuroendocrine prostate cancer (NEPC) subtype. The 5-year project aims to investigate how the transcription factor FOXA2 interacts with NKX2-1 to drive this luminal-to-neuroendocrine transdifferentiation process, including examining the role...